Good
Mostly Aligned
Patient Risk:
Moderate
Summary
Most drug-identity and general mechanism/indication statements align with the provided label excerpts. Several detailed API/quality-specification and formulation claims are not addressed by the provided FDA label text and are therefore unsupported. Safety warning claims generally align with the provided Warnings and Precautions excerpts (not all details are fully substantiated by the provided label text).
Category Scores
Accurate Statements
Tofacitinib citrate is the active pharmaceutical ingredient (API) used in the drug Xeljanz.
Provided label excerpt lists active ingredient(s) as tofacitinib (as tofacitinib citrate).
Xeljanz is a Janus kinase (JAK) inhibitor.
Implied by the provided FDA label excerpt context describing tofacitinib (no explicit phrase provided, so support is partial/indirect).
Tofacitinib citrate is approved for the treatment of moderate to severe rheumatoid arthritis in adults with an inadequate response or intolerance to other therapies.
Not present in the provided excerpts for Section 1 (only PsA and pcJIA are quoted; no RA excerpt shown).
Tofacitinib citrate is approved for the treatment of psoriatic arthritis in adults with an inadequate response or intolerance to other therapies.
Section 1.2 Psoriatic Arthritis excerpt: adult patients with active PsA who had an inadequate response or intolerance to one or more TNF blockers.
Tofacitinib citrate is approved for the treatment of moderate to severe active ulcerative colitis in adults with an inadequate response or intolerance to other therapies.
Not present in the provided excerpts (no UC section excerpt shown).
Patients taking tofacitinib citrate may experience an increased risk of serious infections.
Section 5.1 Serious Infections excerpt: serious and sometimes fatal infections may occur.
Patients taking tofacitinib citrate may experience an increased risk of blood clots.
Section 5.5 Thrombosis excerpt: thrombosis including PE/DVT/arterial thrombosis may occur.
Patients taking tofacitinib citrate may experience an increased risk of certain cancers.
Section 5.3 Malignancy and Lymphoproliferative Disorders excerpt: malignancies have occurred.
Unsupported Statements
An API specification refers to the set of quality standards and tests that the API must meet to ensure purity, potency, and safety.
Not addressed in the provided FDA label excerpts.
Key aspects of an API specification often include identification tests to confirm the identity of the API as tofacitinib citrate.
Not addressed in the provided FDA label excerpts.
Key aspects of an API specification often include an assay to determine the API's strength or potency, typically expressed as a percentage.
Not addressed in the provided FDA label excerpts.
Key aspects of an API specification often include purity limits for impurities, including related substances and residual solvents.
Not addressed in the provided FDA label excerpts.
Key aspects of an API specification often include water content measurement of moisture content.
Not addressed in the provided FDA label excerpts.
Key aspects of an API specification often include heavy metals limits for potentially toxic heavy metal contaminants.
Not addressed in the provided FDA label excerpts.
Key aspects of an API specification often include microbial limits to ensure the API is free from unacceptable levels of microorganisms.
Not addressed in the provided FDA label excerpts.
Key aspects of an API specification often include physical characteristics such as appearance, solubility, and particle size distribution.
Not addressed in the provided FDA label excerpts.
The primary manufacturer of tofacitinib citrate API is Pfizer Inc.
Not addressed in the provided FDA label excerpts.
Tofacitinib is the base drug molecule.
Not addressed in the provided FDA label excerpts.
Tofacitinib citrate is the salt form of tofacitinib combined with citric acid.
Not explicitly addressed in the provided FDA label excerpts.
The citrate salt form is often used in pharmaceutical formulations because it can improve solubility, stability, and bioavailability of the API.
Not addressed in the provided FDA label excerpts.
Tofacitinib citrate is approved for the treatment of moderate to severe rheumatoid arthritis in adults with an inadequate response or intolerance to other therapies.
No rheumatoid arthritis indication excerpt is included in the provided label text.
Tofacitinib citrate is approved for the treatment of moderate to severe active ulcerative colitis in adults with an inadequate response or intolerance to other therapies.
No ulcerative colitis indication excerpt is included in the provided label text.
Patients taking tofacitinib citrate may experience an increased risk of heart attack.
Section 5.4 discusses MACE and MI/stroke discontinuation, but the provided excerpts do not explicitly state 'heart attack' as an increased risk; support is partial/inferential.
Patients taking tofacitinib citrate may experience an increased risk of stroke.
Section 5.4 includes MI or stroke language, but the provided excerpts do not explicitly state 'increased risk of stroke' as such; support is partial/inferential.
Contradictions
Important Omissions
No mention of label-required baseline evaluations prior to initiation (e.g., TB testing, viral hepatitis screening, CBC thresholds) for tofacitinib oral solution, which are relevant to safety monitoring.
Importance:
Moderate
No mention that tofacitinib should be interrupted/avoided in active serious infection until controlled, and that monitoring/interruptions are linked to lymphopenia/neutropenia/anemia lab thresholds.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Safety-related claims are generally directionally aligned with the provided Warnings (serious infections, thrombosis, malignancy), but some cardiovascular claims (heart attack/stroke) are not directly supported by the provided excerpts as stated, and key label monitoring/evaluation instructions are omitted.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several claims (API/manufacturing/physical specification details; exact RA and ulcerative colitis indications; explicit 'heart attack'/'stroke' risk wording) are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit assertions to what is explicitly present in the provided label excerpts (e.g., PsA indication from Section 1.2; serious infections (5.1), malignancy (5.3), thrombosis (5.5)). Remove or qualify unsupported API-quality/manufacturer/formulation claims, and avoid stating 'increased risk of heart attack/stroke' unless the provided label text explicitly supports that wording. Add label-specific baseline evaluation and monitoring/interruption details (TB/hepatitis/CBC thresholds; interrupt for serious infection and for lab abnormalities).